SCHEMBL4408790

SCHEMBL4408790

O=c1cc(-c2cccs2)cc(-c2ccccc2)[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R38 P59533 1/20 0.47
NOTUM Q6P988 1/20 0.44
KDM4E B2RXH2 6/20 0.43
MAPT P10636 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP8 P22894 1/20 0.41
MMP13 P45452 1/20 0.41
HPGD P15428 4/20 0.41
ALDH1A1 P00352 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C9 P11712 2/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
PPARG P37231 1/20 0.41
KMT2A Q03164 1/20 0.41
NCOA2 Q15596 1/20 0.41
NCOA1 Q15788 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8799476 0.87 KDM4E (0.44) TAS2R38NOTUMKDM4EMAPTHPGD
SCHEMBL9522651 0.81 CYP2E1 (0.42) TAS2R38KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL6756097 0.79 TAS2R38 (0.60) TAS2R38NOTUMKDM4EMAPTSMN1; SMN2
SCHEMBL8987259 0.77 TAS2R38 (0.44) TAS2R38NOTUMKDM4EMAPTSMN1; SMN2
SCHEMBL8222273 0.73 KDM4E (0.50) KDM4EMAPTSMN1; SMN2HPGDALDH1A1
SCHEMBL28043530 0.73 KDM4E (0.54) KDM4EMAPTHPGDALDH1A1CYP3A4
SCHEMBL28260510 0.72 GCGR (0.49) KDM4EMAPTHPGDALDH1A1CYP3A4
SCHEMBL31124 0.72 CYP3A4 (0.58) KDM4EMAPTHPGDALDH1A1CYP3A4
SCHEMBL3595434 0.72 TOP1 (0.56) KDM4EMAPTSMN1; SMN2HPGDALDH1A1
SCHEMBL8987160 0.71 CYP2E1 (0.53) TAS2R38NOTUMKDM4EMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1863793-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-07-04 EP disclosed
EP-1863793-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-07-04 EP disclosed
US-20090285774-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-11-19 US disclosed
US-20090285774-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-11-19 US disclosed
US-20090285774-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-11-19 US disclosed
WO-2009140475-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-11-19 WO disclosed
US-7323447-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-01-29 US disclosed
US-7323447-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-01-29 US disclosed
US-7323447-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-01-29 US disclosed
EP-1863793-A2 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2007-12-12 EP disclosed
WO-2006086381-A2 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-08-17 WO disclosed
WO-2006086381-A2 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-08-17 WO disclosed
US-20060183694-A1 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183694-A1 Hepatitis C virus inhibitors HAVCR2, HPN, CTSC TAS2R38 4313/4885NOTUM 1897/4885KDM4E 2561/4885
US-20090285774-A1 Hepatitis C Virus Inhibitors HAVCR2, HCCS, PYGL TAS2R38 4753/4885NOTUM 1137/4885KDM4E 3825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.